Clinical reference Biomarker Directory
Back to directory

AFP

Established

AFP is a fetal plasma protein used as a biomarker for liver and germ cell tumors.

Also known as Alpha-1-fetoprotein alpha-fetoglobulin FETA
In plain language

AFP is normally high before birth but low afterward. A rise can signal liver cancer or certain testicular/ovarian tumors. Regular AFP plus ultrasound checks every six months are standard for people with cirrhosis to catch liver cancer early, and combination scores like GALAD are being studied to improve detection further.

Biomarker & context

Alpha-fetoprotein (AFP) is a fetal glycoprotein produced by the yolk sac and fetal liver; levels drop rapidly after birth and remain low in healthy adults. Re-expression in adulthood signals regenerating liver tissue or certain tumors, making it a longstanding oncology biomarker.

What it indicates

Elevated AFP is a classic marker of hepatocellular carcinoma (HCC), correlating with tumor burden and prognosis, and of nonseminomatous testicular and ovarian germ cell tumors, where it is used with beta-hCG for staging and monitoring.

Diagnosis & clinical testing

AASLD's current guidance recommends AFP plus ultrasound every 6 months for HCC surveillance in cirrhotic patients, explicitly not recommending routine CT/MRI or AFP-L3%/DCP alone for surveillance. The GALAD score (gender, age, AFP, AFP-L3%, DCP) is the most-cited composite model for early HCC detection, though EASL 2024 guidance cautions it is not yet validated enough for routine screening due to selection bias in underlying studies. AFP ≥200 ng/mL without a visible lesion should prompt alternate imaging.

Guiding treatment

Serial AFP tracks treatment response and recurrence in HCC and germ cell tumors; rising AFP during surveillance in a cirrhotic patient triggers diagnostic multiphase CT or MRI regardless of ultrasound findings.

Clinical significance

Elevated in hepatocellular carcinoma and testicular/ovarian germ cell tumors; core to HCC surveillance guidelines.

References
  1. AASLD Practice Guidance on Hepatocellular Carcinoma. (2023). PMC.
  2. EASL Clinical Practice Guidelines on the Management of Hepatocellular Carcinoma. (2024). Journal of Hepatology.
  3. Nartey, Y. A., et al. (2024). GALAD Score for the Diagnosis of HCC in Sub-Saharan Africa. Cancer Research Communications.